Familial Donated NK Cell Therapy
Nikcell 2 is a haploidentical natural killer (NK) cell therapy that empowers the immune system’s innate ability to recognize and eliminate cancer cells. Derived from healthy, partially HLA-matched donors, Nikcell 2 is manufactured under GMP-aligned standards, ensuring safety, consistency, therapeutic potency, and applied for systematic use.
It is currently being evaluated in clinical studies targeting selected metastatic solid tumors.
At this stage, Nikcell 2 remains under controlled clinical investigation, with availability limited to enrolled study participants.
The research and development of Nikcell 2 began in 2020 at the Royan Institute, in collaboration with Tehran University of Medical Sciences, under GMP-compliant conditions.
The Phase I clinical trial, initiated in 2021, investigated intralesional administration of activated NK cells in patients with recurrent malignant brain tumors. The study demonstrated that multiple injections were safe, feasible, and clinically promising, with encouraging signs of disease control and extended survival.
Results of this trial were published in 2023 , providing a strong foundation for Nikcell 2’s continued clinical development and future expansion into broader oncological indications.
Kian Immune Cell continues to advance Nikcell 2 through clinical development and optimization, refining donor selection, expansion protocols, and quality control to ensure scalability and global clinical readiness.
The MR images of a patient who received the NK cells and followed up based on the approved protocol in the present study. NK cells were infused exactly at the surgery site post-healing the lesions.